
Repligen Corporation RGEN
$ 163.68
-3.99%
Repligen Corporation Interest Expense | RGEN
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Repligen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.82 M | -5.17 M | 1.95 M | 1.16 M | 11.3 M | 10.8 M | 9.29 M | 6.71 M | 6.44 M | 3.77 M | 32 K | 50 K | 50 K | 56.7 K | 26.2 K | 12.7 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.3 M | -5.17 M | 3.08 M |
Quarterly Interest Expense Repligen Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.91 M | -273 K | -750 K | 403 K | -804 K | 3.5 M | -286 K | -4.53 M | 3.1 M | -215 K | -3.54 M | 6.62 M | 895 K | 528 K | 77 K | 858 K | -6.59 M | -3.4 M | -402 K | 621 K | -786 K | -779 K | -224 K | - | 3.05 M | 3 M | 2.98 M | -291 K | 316 K | -697 K | 358 K | 75 K | -134 K | 251 K | 71 K | -139 K | 1.62 M | 1.6 M | 1.58 M | 119 K | 1.56 M | 638 K | 5 K | -270 K | 8 K | 8 K | 9 K | -12 K | 11 K | 13 K | 14 K | -12 K | 11.7 K | 12.4 K | 13.5 K | -14 K | -7 K | 27.4 K | 22.4 K | 28 K | 13.5 K | 13.5 K | 13 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.62 M | -6.59 M | 191 K |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Ekso Bionics Holdings
EKSO
|
-8 K | - | - | $ 28.6 M | ||
|
Isoray
ISR
|
84 K | - | 0.03 % | $ 108 M | ||
|
Masimo Corporation
MASI
|
300 K | - | - | $ 9.59 B | ||
|
Stereotaxis
STXS
|
2 K | $ 0.95 | -6.44 % | $ 86.4 M | ||
|
Predictive Oncology
POAI
|
3 | - | - | $ 31.1 M | ||
|
BioLife Solutions
BLFS
|
1.82 M | $ 38.61 | 3.51 % | $ 1.84 B | ||
|
Utah Medical Products
UTMD
|
-120 K | $ 70.46 | -0.7 % | $ 228 M | ||
|
West Pharmaceutical Services
WST
|
-1 M | $ 389.88 | -1.72 % | $ 28.2 B | ||
|
Baxter International
BAX
|
290 M | $ 25.39 | -0.02 % | $ 13 B | ||
|
Glaukos Corporation
GKOS
|
479 K | $ 236.75 | -0.63 % | $ 13.5 B | ||
|
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M | ||
|
Milestone Scientific
MLSS
|
60.3 K | $ 0.24 | -0.83 % | $ 19.7 M | ||
|
Alcon
ALC
|
204 M | $ 74.29 | -0.32 % | $ 36.6 B | ||
|
AtriCure
ATRC
|
683 K | $ 55.37 | 2.33 % | $ 2.64 B | ||
|
Becton, Dickinson and Company
BDX
|
613 M | $ 212.18 | -0.26 % | $ 61 B | ||
|
AngioDynamics
ANGO
|
3.93 M | $ 10.8 | 0.37 % | $ 448 M | ||
|
The Cooper Companies
COO
|
-16.4 M | $ 58.8 | -2.54 % | $ 11.7 B | ||
|
Repro Med Systems
KRMD
|
9.91 K | $ 3.19 | -7.41 % | $ 147 M | ||
|
InfuSystem Holdings
INFU
|
2 K | $ 14.39 | 2.35 % | $ 297 M | ||
|
electroCore
ECOR
|
14.9 K | $ 4.5 | -7.22 % | $ 38.2 M | ||
|
OraSure Technologies
OSUR
|
229 K | $ 3.48 | -3.6 % | $ 256 M | ||
|
iRhythm Technologies
IRTC
|
5.44 M | $ 94.92 | 0.72 % | $ 3.04 B | ||
|
ResMed
RMD
|
-9.15 M | $ 235.13 | -0.78 % | $ 34.2 B | ||
|
Harvard Bioscience
HBIO
|
-2.66 M | $ 8.62 | -0.69 % | $ 383 M | ||
|
Retractable Technologies
RVP
|
152 K | $ 0.56 | -6.53 % | $ 16.8 M | ||
|
Microbot Medical
MBOT
|
-5 K | $ 0.68 | -8.79 % | $ 31.1 M | ||
|
Haemonetics Corporation
HAE
|
-28.7 M | $ 119.94 | -0.3 % | $ 5.66 B | ||
|
STERIS plc
STE
|
9.8 M | $ 255.68 | 0.31 % | $ 25.1 B | ||
|
ICU Medical
ICUI
|
93.3 M | $ 172.0 | -2.14 % | $ 4.24 B | ||
|
Merit Medical Systems
MMSI
|
-2.39 M | $ 84.35 | -0.07 % | $ 4.99 B | ||
|
Nephros
NEPH
|
-78 K | $ 2.72 | -4.26 % | $ 28.9 M | ||
|
Pro-Dex
PDEX
|
533 K | $ 62.2 | -2.03 % | $ 201 B | ||
|
Envista Holdings Corporation
NVST
|
-2.3 M | $ 22.85 | -1.63 % | $ 3.84 B | ||
|
LeMaitre Vascular
LMAT
|
5.18 M | $ 73.73 | -1.52 % | $ 1.67 B | ||
|
Pulse Biosciences
PLSE
|
-52 K | $ 45.42 | 2.27 % | $ 3.06 B | ||
|
STAAR Surgical Company
STAA
|
2.25 M | $ 24.2 | -3.32 % | $ 1.2 B | ||
|
Teleflex Incorporated
TFX
|
85.1 M | $ 161.56 | -1.16 % | $ 7.21 B | ||
|
DENTSPLY SIRONA
XRAY
|
24 M | $ 8.27 | -2.65 % | $ 1.65 B |